Key result
The MicroMed DeBakey VAD, an axial continuous-flow pump, initially produces nonpulsatile blood flow that becomes increasingly pulsatile as the unloaded left ventricle recovers contractility.
Why the study?
Does the MicroMed DeBakey VAD provide adequate blood flow and end-organ perfusion compared to pulsatile devices in patients with heart failure?
Observational (n=16)
Yes
Does the MicroMed DeBakey VAD provide adequate blood flow and end-organ perfusion compared to pulsatile devices in patients with heart failure?
The MicroMed DeBakey VAD, an axial continuous flow pump, provides effective hemodynamic support and maintains end-organ function comparably to traditional pulsatile devices, with flow becoming pulsatile as the native ventricle recovers.
The results obtained in over 100 patients implanted with the MicroMed DeBakey VAD in several centers in Europe and USA (September 2001, M. Loebe, personal communication) demonstrate that the effectiveness of the MicroMed DeBakey VAD is comparable to that of the pulsatile devices and that it also shows some superior properties. Recently, other axial pumps--the Jarvic 2000 (72) and HeartMate II (73)--have come into clinical use. Because the patients show good tolerance of the nonpulsatile blood flow in the early postoperative period, and pulsatility increased with recovery of the left ventricle because of unloading, we believe that the axial pumps will gain wide acceptance and provide a new option in the treatment of heart failure.
No takes yet. Share an insight, caveat, or question.
Potapov et al. (2003) conducted an observational in End-stage heart failure (n=16). MicroMed DeBakey VAD vs. Novacor LVAD was evaluated. The MicroMed DeBakey VAD, an axial continuous-flow pump, initially produces nonpulsatile blood flow that becomes increasingly pulsatile as the unloaded left ventricle recovers contractility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: